Print |
  • Text A A
  • PDxProstateSubPageGraphic.png

    SOUND SCIENCE

    UroVysion:

    Halling, K. C., King, W., Sokolova, I. A., Meyer, R. G., Burkhardt, H. M., Halling, A. C. et al: A Comparison of Cytology and Fluorescence In Situ Hybridization for the Detection of Urothelial Carcinoma. J Urol164: 1768, 2000

    Sarosdy, M. F., Schellhammer, P., Bokinsky, G., Kahn, P., Chao, R., Yore, L. et al: Clinical Evaluation of a Multi-Target Fluorescent In Situ Hybridization Assay for the Detection of Bladder Cancer. J Urol168: 1950, 2002

    Sarosdy, M.F., Kahn, P.R., Ziffer, M.D., Love, W.R., Barkin, J., Abara, E. O. et al: Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria. J Urol176: 44, 2006

    ALK:

    Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-567

    Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer.J Clin Oncol. 2009;27:4232-4235

    Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.2009;27:4247-4253

    Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703

    Mino-Kenudson and Mark, Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med. Vol 134, May 2011. 655-664

    Choi, et al. Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer. Cancer Res.2008;68(13):4971-6

    Rodig SJ , Mino-Kenudson M , Dacic S , et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15:5216-5223

    ERG:

    Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology. 2011;24:1511-1520.

    Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS-ERG Gene Fusion is Not Associated with Outcome in Patients Treated by Prostatectomy. Cancer Research. 2009;69(4):1400-1406.

    Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253–263.

    PTEN:

    Reid AHM, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. British Journal of Cancer. 2010;102(4):678-684.

    Krohn A, Diedler T, Burkhardt L, et al. Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative. Prostate Cancer. The American Journal of Pathology. 2012;181(2):401–412.

    Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer. 2007;97:678-685.